-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
Program Covers Broad Spectrum of Topics in Thoracic Oncology
The chairs of WCLC 2023 say this year’s program offers something for everyone, including practice-changing clinical trial data and innovative basic science as well as presentations to address broader needs within the profession.
-
Demystifying AI: Current Insights on Artificial Intelligence in Thoracic Oncology
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field.
-
Artificial Intelligence in Healthcare: A Patient Perspective
When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more.
-
ELCC Session Offers Surgical Perspective in Context of Neoadjuvant Immunotherapy
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC.
-
Staging Experts Offer Insights on Challenges of Nodal Classification
Adding to the discussion, Drs. David Ball, Daniel Steinfort, and Susan Harden propose alternative approaches for the complex task of improving nodal staging.
-
Thoracic Oncologists Divided Regarding Role of Neoadjuvant Chemoimmunotherapy
Consensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC.
-
From the Editors April 12, 2023
ILCN Associate Editors Drs. Suresh Senan and Witold Rzyman add clinical perspective to surveillance frequency discussion.
-
New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC.
-
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint.
-
Patient Perspective: ‘Scanxiety’ Triggered by Cancer, Not Scans
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning.
View ILCN Archives
Provider Resources
Popular Articles